Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantourage Group SEFRA:HIGH 20 EV-to-EBITDA is 1,344.24 as of Aug. 11, 2026. GuruFocus rates FRA:HIGH with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 736 Drug Manufacturers companies, Cantourage Group SE ranks worse than 99.73% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cantourage Group SE's enterprise value is €60.49 Mil.
Cantourage Group SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €0.05 Mil. Therefore, Cantourage Group SE's EV-to-EBITDA for today is 1,344.24.
The historical rank and industry rank for Cantourage Group SE's EV-to-EBITDA or its related term are showing as below:
FRA:HIGH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -428.47 Med: -212.31 Max: 5523.66
Current: 1344.24
During the past 5 years, the highest EV-to-EBITDA of Cantourage Group SE was 5523.66. The lowest was -428.47. And the median was -212.31.
FRA:HIGH's EV-to-EBITDA is ranked worse than 99.73% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.185
vs FRA:HIGH: 1344.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cantourage Group SE (FRA:HIGH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cantourage Group SE's PE Ratio (TTM) for today is calculated as:
Cantourage Group SE's share price for today is €5.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cantourage Group SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cantourage Group SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HIGH vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's EV-to-EBITDA falls into.
Cantourage Group SE's current Enterprise Value is €60.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cantourage Group SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE (FRA:HIGH) has a EV-to-EBITDA of 1,344.24 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cantourage Group SE. According to the industry distribution chart, Cantourage Group SE ranks #734 out of 736 companies in the Drug Manufacturers industry, placing it in the top 99.7%.
Is Cantourage Group SE's EV-to-EBITDA too high?
Cantourage Group SE's current EV-to-EBITDA is 1,344.24. The Drug Manufacturers industry median EV-to-EBITDA is 13.19. Cantourage Group SE's value of 1,344.24 is 10095.2% above this industry median. Based on the distribution chart, Cantourage Group SE ranks #734 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cantourage Group SE has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #734 out of 736 companies for EV-to-EBITDA. This places Cantourage Group SE in the lower half of its industry. The industry median EV-to-EBITDA is 13.19. Cantourage Group SE's value of 1,344.24 is 10095.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.19, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current EV-to-EBITDA of 1,344.24 is 10095.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cantourage Group SE. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current EV-to-EBITDA is 1,344.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (FRA:HIGH) has a current EV-to-EBITDA of 1,344.24. The current EV-to-EBITDA is 1,344.24 and 10095.2% above the Drug Manufacturers industry median of 13.19. Cantourage Group SE's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cantourage Group SE (FRA:HIGH), the current EV-to-EBITDA is 1,344.24 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
20GF Score
Get the complete analysis for FRA:HIGH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HIGH has been successfully added to your 
